Anavex Life Sciences (NASDAQ:AVXL) issued its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.01, Morningstar.com reports.
Shares of NASDAQ AVXL opened at $2.89 on Friday. Anavex Life Sciences has a 1-year low of $1.25 and a 1-year high of $4.35.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Deutsche Bank AG bought a new stake in Anavex Life Sciences in the 4th quarter worth $28,000. Jane Street Group LLC bought a new stake in shares of Anavex Life Sciences during the 1st quarter valued at about $39,000. Wedbush Securities Inc. bought a new stake in shares of Anavex Life Sciences during the 1st quarter valued at about $43,000. Charles Schwab Investment Management Inc. bought a new stake in shares of Anavex Life Sciences during the 1st quarter valued at about $49,000. Finally, ExodusPoint Capital Management LP bought a new stake in shares of Anavex Life Sciences during the 1st quarter valued at about $49,000. Hedge funds and other institutional investors own 15.01% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Anavex Life Sciences (AVXL) Issues Quarterly Earnings Results” was originally published by Rockland Register and is the property of of Rockland Register. If you are reading this news story on another site, it was stolen and republished in violation of US and international copyright & trademark laws. The correct version of this news story can be viewed at https://rocklandregister.com/2019/06/01/anavex-life-sciences-avxl-posts-quarterly-earnings-results-beats-expectations-by-0-01-eps.html.
Anavex Life Sciences Company Profile
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system diseases. The company's lead drug candidate is ANAVEX 2-73, which has completed Phase 2a clinical trial for Alzheimer's disease; and preclinical clinical trials to treat Parkinson's disease, Rett syndrome, epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis.
See Also: Why Net Income is Important to Investors
Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.